JP2000506511A - ペルフルオロアルキル含有金属錯体、その製造方法及びnmr―診断薬への応用 - Google Patents
ペルフルオロアルキル含有金属錯体、その製造方法及びnmr―診断薬への応用Info
- Publication number
- JP2000506511A JP2000506511A JP9525698A JP52569897A JP2000506511A JP 2000506511 A JP2000506511 A JP 2000506511A JP 9525698 A JP9525698 A JP 9525698A JP 52569897 A JP52569897 A JP 52569897A JP 2000506511 A JP2000506511 A JP 2000506511A
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- compound
- mmol
- complex
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 150000004696 coordination complex Chemical class 0.000 title claims abstract description 8
- 125000005010 perfluoroalkyl group Chemical group 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 368
- 239000002872 contrast media Substances 0.000 claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 229
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 188
- 239000000203 mixture Substances 0.000 claims description 104
- 239000007983 Tris buffer Substances 0.000 claims description 100
- -1 amine amide Chemical class 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 75
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 54
- 150000008064 anhydrides Chemical class 0.000 claims description 48
- 125000006239 protecting group Chemical group 0.000 claims description 45
- 239000002253 acid Substances 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 150000007530 organic bases Chemical class 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000007529 inorganic bases Chemical class 0.000 claims description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 150000004885 piperazines Chemical class 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- XDLOGHYCUQYEKA-UHFFFAOYSA-N 2-(1,4,7,10-tetrazacyclododec-1-yl)acetic acid Chemical compound OC(=O)CN1CCNCCNCCNCC1 XDLOGHYCUQYEKA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 150000002366 halogen compounds Chemical class 0.000 claims description 2
- 150000001261 hydroxy acids Chemical class 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims 4
- 150000004706 metal oxides Chemical class 0.000 claims 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 238000003325 tomography Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000002587 lymphangiography Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 240
- 239000000243 solution Substances 0.000 description 166
- 238000000921 elemental analysis Methods 0.000 description 150
- 238000003756 stirring Methods 0.000 description 139
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- 239000007787 solid Substances 0.000 description 116
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 99
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 94
- 238000005259 measurement Methods 0.000 description 90
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 88
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 87
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 82
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 81
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 74
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 72
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 57
- 239000012074 organic phase Substances 0.000 description 55
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
- 229910052688 Gadolinium Inorganic materials 0.000 description 48
- 238000004587 chromatography analysis Methods 0.000 description 44
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 40
- 239000000706 filtrate Substances 0.000 description 38
- 239000007788 liquid Substances 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 35
- 238000010898 silica gel chromatography Methods 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 235000011121 sodium hydroxide Nutrition 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000000284 extract Substances 0.000 description 28
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 27
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 26
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 26
- 235000019341 magnesium sulphate Nutrition 0.000 description 26
- 239000012071 phase Substances 0.000 description 26
- 239000000126 substance Substances 0.000 description 25
- 238000012546 transfer Methods 0.000 description 23
- 239000003054 catalyst Substances 0.000 description 22
- 210000001165 lymph node Anatomy 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 229940075613 gadolinium oxide Drugs 0.000 description 20
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 20
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 20
- 239000012153 distilled water Substances 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 14
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- ZZYIFALPSYDLCC-UHFFFAOYSA-N 6,6-dichlorohexylurea Chemical compound NC(=O)NCCCCCC(Cl)Cl ZZYIFALPSYDLCC-UHFFFAOYSA-N 0.000 description 12
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 229910052763 palladium Inorganic materials 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 235000011181 potassium carbonates Nutrition 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 9
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 229940072033 potash Drugs 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229960005335 propanol Drugs 0.000 description 7
- 229960002317 succinimide Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000009918 complex formation Effects 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 150000004714 phosphonium salts Chemical class 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 5
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 4
- FSQQMRBMRQRJLT-UHFFFAOYSA-N 2-[2-[carboxymethyl-[2-[carboxymethyl(ethyl)amino]ethyl]amino]ethyl-ethylamino]acetic acid Chemical compound OC(=O)CN(CC)CCN(CC(O)=O)CCN(CC)CC(O)=O FSQQMRBMRQRJLT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000007239 Wittig reaction Methods 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 239000013065 commercial product Substances 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 229910017464 nitrogen compound Inorganic materials 0.000 description 4
- 150000002830 nitrogen compounds Chemical class 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 150000000921 Gadolinium Chemical class 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000007098 aminolysis reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000006612 decyloxy group Chemical group 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 150000002222 fluorine compounds Chemical class 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 3
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BCFSXOVYBUXNCH-UHFFFAOYSA-N 2-[4-(3-amino-2-hydroxypropyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound NCC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 BCFSXOVYBUXNCH-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- 229910052769 Ytterbium Inorganic materials 0.000 description 2
- OORZSBKWNCNMFV-UHFFFAOYSA-N [N]CCCCCC(Cl)Cl Chemical compound [N]CCCCCC(Cl)Cl OORZSBKWNCNMFV-UHFFFAOYSA-N 0.000 description 2
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- MOFPHFUGHSLAIR-UHFFFAOYSA-I disodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;dysprosium(3+) Chemical compound [Na+].[Na+].[Dy+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O MOFPHFUGHSLAIR-UHFFFAOYSA-I 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002258 gallium Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JCDQGOSXWGXOQQ-UHFFFAOYSA-H ytterbium(3+);tricarbonate Chemical compound [Yb+3].[Yb+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O JCDQGOSXWGXOQQ-UHFFFAOYSA-H 0.000 description 2
- 150000003752 zinc compounds Chemical class 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- PPKPKFIWDXDAGC-IHWYPQMZSA-N (z)-1,2-dichloroprop-1-ene Chemical group C\C(Cl)=C\Cl PPKPKFIWDXDAGC-IHWYPQMZSA-N 0.000 description 1
- OZCRKDNRAAKDAN-IWQZZHSRSA-N (z)-but-1-ene-1,4-diol Chemical compound OCC\C=C/O OZCRKDNRAAKDAN-IWQZZHSRSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- UCCYEAVBELUTSI-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-n-hexyloctane-1-sulfonamide Chemical compound CCCCCCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UCCYEAVBELUTSI-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- IEAPQKXYYBULMH-UHFFFAOYSA-N 1-methyl-1,4,7,10-tetrazacyclododecane Chemical compound CN1CCNCCNCCNCC1 IEAPQKXYYBULMH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IUDGNRWYNOEIKF-UHFFFAOYSA-N 11-bromo-undecanoic acid Chemical compound OC(=O)CCCCCCCCCCBr IUDGNRWYNOEIKF-UHFFFAOYSA-N 0.000 description 1
- MFGSZRPFMNFGPD-UHFFFAOYSA-N 2-[1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl(hexyl)amino]acetic acid Chemical compound CCCCCCN(CC(O)=O)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F MFGSZRPFMNFGPD-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SKRBGTOAJPFYBO-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[2-[2-[[2-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetyl]amino]ethylamino]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound CCN(CC(=O)NCCNC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SKRBGTOAJPFYBO-UHFFFAOYSA-N 0.000 description 1
- PGIVNKJNVKROAZ-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[3-[[2-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetyl]amino]-2-hydroxypropyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(CC)CC(=O)NCC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 PGIVNKJNVKROAZ-UHFFFAOYSA-N 0.000 description 1
- MXNLINQJLGGQQU-UHFFFAOYSA-N 2-[benzyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetic acid Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(CC(=O)O)CC1=CC=CC=C1 MXNLINQJLGGQQU-UHFFFAOYSA-N 0.000 description 1
- HUVKUIZTLXVCLI-UHFFFAOYSA-N 2-[decyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetic acid Chemical compound CCCCCCCCCCN(CC(O)=O)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F HUVKUIZTLXVCLI-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- JVLRBIADOALMLB-UHFFFAOYSA-N 2-ethoxy-1,2-dihydroquinoline Chemical compound C1=CC=C2C=CC(OCC)NC2=C1 JVLRBIADOALMLB-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- PXVANOWCPYSZHN-UHFFFAOYSA-N 2-morpholin-4-yl-n-(1,3,3,5-tetramethylcyclohexyl)acetamide;hydrochloride Chemical compound Cl.C1C(C)CC(C)(C)CC1(C)NC(=O)CN1CCOCC1 PXVANOWCPYSZHN-UHFFFAOYSA-N 0.000 description 1
- CKICBBJJCUQLPO-UHFFFAOYSA-N 2-oxaspiro[4.5]decan-3-one Chemical compound C1OC(=O)CC21CCCCC2 CKICBBJJCUQLPO-UHFFFAOYSA-N 0.000 description 1
- KDGIOTBLYAPNRR-UHFFFAOYSA-N 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecanal Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CC=O KDGIOTBLYAPNRR-UHFFFAOYSA-N 0.000 description 1
- WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XXXVGNQOSNGIQW-UHFFFAOYSA-N CCCCCCCCCC.N1CCNCCNCCNCC1 Chemical compound CCCCCCCCCC.N1CCNCCNCCNCC1 XXXVGNQOSNGIQW-UHFFFAOYSA-N 0.000 description 1
- BEXUOOWFMFFAHS-UHFFFAOYSA-N CCNCCNCC(C(C1=CC=CC=C1)O)NCC Chemical compound CCNCCNCC(C(C1=CC=CC=C1)O)NCC BEXUOOWFMFFAHS-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001066681 Homo sapiens Integrase Proteins 0.000 description 1
- 238000006052 Horner reaction Methods 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CKRXVVGETMYFIO-UHFFFAOYSA-N N-ethylperfluorooctane sulfonamidoacetic acid Chemical compound OC(=O)CN(CC)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CKRXVVGETMYFIO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- ZFVLZXXZUGHWSP-UHFFFAOYSA-L N1=CN=CC=C1.[Cr](=O)(=O)(O)Cl Chemical compound N1=CN=CC=C1.[Cr](=O)(=O)(O)Cl ZFVLZXXZUGHWSP-UHFFFAOYSA-L 0.000 description 1
- RUQJSXVXJAAYLY-UHFFFAOYSA-N NCCNC(=O)CN(CC)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F Chemical compound NCCNC(=O)CN(CC)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUQJSXVXJAAYLY-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- BSUZXTZVGHULPU-UHFFFAOYSA-N OC([Gd])=O Chemical compound OC([Gd])=O BSUZXTZVGHULPU-UHFFFAOYSA-N 0.000 description 1
- BHFJBHMTEDLICO-UHFFFAOYSA-N Perfluorooctylsulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O BHFJBHMTEDLICO-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241001115903 Raphus cucullatus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 241000051616 Ulmus minor Species 0.000 description 1
- 150000001224 Uranium Chemical class 0.000 description 1
- CTYVBSGIFONFHX-UHFFFAOYSA-N [Mn].[Gd] Chemical class [Mn].[Gd] CTYVBSGIFONFHX-UHFFFAOYSA-N 0.000 description 1
- PITVMTAGTWAAKI-UHFFFAOYSA-H [U+6].OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O Chemical compound [U+6].OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O PITVMTAGTWAAKI-UHFFFAOYSA-H 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- MOOSBPSAZDOBSN-UHFFFAOYSA-N acetic acid;azane Chemical compound N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O MOOSBPSAZDOBSN-UHFFFAOYSA-N 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010081218 albumin-(gadolinium-DTPA) Proteins 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IIDNACBMUWTYIV-VIFPVBQESA-N benzyl (2s)-2-amino-3-hydroxypropanoate Chemical compound OC[C@H](N)C(=O)OCC1=CC=CC=C1 IIDNACBMUWTYIV-VIFPVBQESA-N 0.000 description 1
- DFFKYZGMVXOQHM-UHFFFAOYSA-N benzyl 11-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]undecanoate Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(CC)CCCCCCCCCCC(=O)OCC1=CC=CC=C1 DFFKYZGMVXOQHM-UHFFFAOYSA-N 0.000 description 1
- WJKJXKRHMUXQSL-UHFFFAOYSA-N benzyl glycinate 4-methylbenzenesulfonate salt Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)OCC1=CC=CC=C1 WJKJXKRHMUXQSL-UHFFFAOYSA-N 0.000 description 1
- HRSXWUSONDBHSP-UHFFFAOYSA-N benzyl hexanoate Chemical compound CCCCCC(=O)OCC1=CC=CC=C1 HRSXWUSONDBHSP-UHFFFAOYSA-N 0.000 description 1
- FOHGPRAJGVHHFX-UHFFFAOYSA-M bis(2-methylpropyl)alumanylium;hydroxide Chemical compound [OH-].CC(C)C[Al+]CC(C)C FOHGPRAJGVHHFX-UHFFFAOYSA-M 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000005521 carbonamide group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000011411 digital subtraction method Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BLBBMBKUUHYSMI-UHFFFAOYSA-N furan-2,3,4,5-tetrol Chemical compound OC=1OC(O)=C(O)C=1O BLBBMBKUUHYSMI-UHFFFAOYSA-N 0.000 description 1
- IZZTUGMCLUGNPM-UHFFFAOYSA-K gadolinium(3+);triiodide Chemical compound I[Gd](I)I IZZTUGMCLUGNPM-UHFFFAOYSA-K 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- OFXSXYCSPVKZPF-UHFFFAOYSA-N methoxyperoxymethane Chemical compound COOOC OFXSXYCSPVKZPF-UHFFFAOYSA-N 0.000 description 1
- ZWAGYOCZRCFLRP-UHFFFAOYSA-N methyl 2-(1,4,7,10-tetrazacyclododec-1-yl)acetate Chemical compound COC(=O)CN1CCNCCNCCNCC1 ZWAGYOCZRCFLRP-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- KJODALGXCUSVFI-UHFFFAOYSA-N n-decyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonamide Chemical compound CCCCCCCCCCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F KJODALGXCUSVFI-UHFFFAOYSA-N 0.000 description 1
- TYWRTWIDTAHEEU-UHFFFAOYSA-N n-ethyl-n'-[2-(ethylamino)ethyl]ethane-1,2-diamine Chemical compound CCNCCNCCNCC TYWRTWIDTAHEEU-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- BDBDSYCJVGJQNK-UHFFFAOYSA-N non-7-en-1-ol Chemical compound CC=CCCCCCCO BDBDSYCJVGJQNK-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 230000005414 paramagnetic center Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 1
- 125000005007 perfluorooctyl group Chemical group FC(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108700020395 polylysine-(Gd-DTPA) Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- VWUPQQFMCOQIEJ-UHFFFAOYSA-M potassium;hydrogen carbonate;hydrate Chemical compound O.[K+].OC([O-])=O VWUPQQFMCOQIEJ-UHFFFAOYSA-M 0.000 description 1
- LUMVCLJFHCTMCV-UHFFFAOYSA-M potassium;hydroxide;hydrate Chemical compound O.[OH-].[K+] LUMVCLJFHCTMCV-UHFFFAOYSA-M 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- AMVCMHXBGWPOTF-UHFFFAOYSA-N sulfane;tetrabutylazanium Chemical compound S.CCCC[N+](CCCC)(CCCC)CCCC AMVCMHXBGWPOTF-UHFFFAOYSA-N 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical compound CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- MSBZOEKTFUFFLH-UHFFFAOYSA-N tert-butyl 2-[1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl(hexyl)amino]acetate Chemical compound CCCCCCN(CC(=O)OC(C)(C)C)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F MSBZOEKTFUFFLH-UHFFFAOYSA-N 0.000 description 1
- VHJVWVSDPWSJRH-UHFFFAOYSA-N tert-butyl 2-[benzyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetate Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)N(CC(=O)OC(C)(C)C)CC1=CC=CC=C1 VHJVWVSDPWSJRH-UHFFFAOYSA-N 0.000 description 1
- GNAWOQMRBUDXMM-UHFFFAOYSA-N tert-butyl 2-[decyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetate Chemical compound CCCCCCCCCCN(CC(=O)OC(C)(C)C)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F GNAWOQMRBUDXMM-UHFFFAOYSA-N 0.000 description 1
- NEQCFDOXEUJNPD-UHFFFAOYSA-N tert-butyl 2-[ethyl(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctylsulfonyl)amino]acetate Chemical compound CC(C)(C)OC(=O)CN(CC)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NEQCFDOXEUJNPD-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/14—Linings or internal coatings
- B65D25/16—Loose, or loosely-attached, linings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
- B65D47/08—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages having articulated or hinged closures
- B65D47/0804—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages having articulated or hinged closures integrally formed with the base element provided with the spout or discharge passage
- B65D47/0833—Hinges without elastic bias
- B65D47/0847—Hinges without elastic bias located within a flat surface of the base element
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/0055—Containers or packages provided with a flexible bag or a deformable membrane or diaphragm for expelling the contents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式I: RF−L−A I 〔式中: RFはフルオル化した直鎖もしくは分枝状の式−CnF2nXで表される炭素鎖で あり、 当該式中のXが フッ素、塩素、臭素、ヨード又は水素原子であり、 nが4〜30の間の数字であり; Lは直接結合、メチレン基、−NHCO−基、又は: (式中のpは0から10の数字であり、q及びuは相互に独立して数字0か1 であり、そして R1は水素分子、メチル基、−CH2−OH−基、−CH2−CO2H基又はC2 −C15の鎖であり、これは、1から3個の酸素原子、1から2個の>CO−基も しくはアリール基により切断されていてもよくそして/又は1から4個のヒドロ キシル基、1から2個のC1−C4−アルコキシ基、1から2個のカルボキシ基も しくは−SO3H−基で置換されていてもよい)により表わされる基、 あるいは直鎖、分枝状、飽和あるいは不飽和型のC2−C30−炭素鎖であって 、これは場合によっては1から10個の酸素原子、1から3個の−NR1一基、 1から2個の硫黄原子、ピペラジン、CONR1−基、NR1CO−基、−SO2 −基、NR1−CO2−基、1から2個の−CO−基、 換型されたアリールを含むこともあり、そして/または当該基により中断されて いることもあり、そして/または場合によっては1から3個の−OR1−基、1 から2個のオキソ基、1から2個の−NH−COR1−基、1から2個の−CO NHR1一基、1から2個の−(CH2)p−CO2H−基、1から2個の−(CH2 )p−(O)q−CH2CH2−RF基で置換されていることもあり、当該基中の、 R1,RF,p及びqは前記と同意であり、そして TはC2−C10−鎖であり、時に1個から2個の酸素原子もしくは1から2個 の−NHCO−基で切断されることがあり; Aは錯体形成体又は金属錯体、あるいはその有機および/又は無機塩基の塩又 はアミノ酸もしくはアミン酸アミドであり、そして特に 一般式II: (式中、R3,Z1、およびYは互いに独立しており、かつ R3はR1と同意であり、又はmが0,1もしくは2であり、LとRFが前記に 同意である−(CH2)m−L−RFであり、 Z1はそれぞれ独立に水素又は原子番号21〜29,39,42 ,44もしくは57〜83の金属イオンであり、 Yは−OZ1−又は であり、式中のZ1、L、RF,およびR3は前記に同意である)の鎖形成体又は 錯体;あるいは、 式中のR3とZ1が前記に同意であり、R2はR1とが同じである一般式III:の錯体形成体又は錯体;あるいは、 式中のZ1が前記に同意である一般式IV: の錯体形成体又は錯体;あるいは、 式中のZ1が前記に同意であり、oとqが0か1であり、その合計o+q=1 である一般式V: の錯体形成体又は錯体;あるいは、 式中のZ1が前記に同意である一般式VI:の錯体形成体又は錯体;あるいは、 式中のZ1とYが前記に同意である一般式VII: の錯体形成体又は錯体;あるいは、 式中のR3とZ1が前記に同意であり、そしてR2がR1と同意である一般式VIII : の錯体形成体又は錯体;あるいは、 式中のR3とZ1が前記に同意である一般式IX:の錯体形成体又は錯体;あるいは、 式中のR3とZ1が前記に同意である一般式X: の錯体形成体又は錯体;あるいは、 式中のZ1pとqが前記に同意であり、そしてR2がR1と同じである一般式X I: の錯体形成体又は錯体;あるいは、 式中のL、RF及びZ1が前記に同意である一般式XII:の錯体形成体又は錯体;あるいは、 式中のZ1が前記に同意である一般式XIII: の錯体形成体もしくは錯体;である〕 による表わされるペルフルオロアリル含有化合物。 2.Z1が水素原子であることを特徴とする請求項1に記載の化合物。 3.式−CnF2nXのnが4〜15の間の数字であることを特徴 とする請求項1又は2に記載の化合物。 4.式−CnF2nXのXがフッ素原子であることを特徴とする請求項1〜3の いずれか1に記載の化合物。 5.Lが次のもの: であることを特徴とする請求項1〜4のいずれか1項に記載の化合物。 6.次の化合物: 10−[2−ヒドロキシ−4−アザ−5−オキソ−7−アザ−7−(ペルフル オロオクチルスルフォニル)−ノニル]−1,4,7−トリス(カルボキシメチ ル)−1,4,7,10−テトラアザシクロドデカンのカドリニウム−錯体、又 は10−[2−ヒドロキシ−4−アザ−5−オキソ−7−オキサ−10,10, 11,11,12,12,13,13,14,14,15,15,16,16, 17,17,17−ヘプタデカフルオロ−ヘプタデシル]−1,4,7−トリス (カルボキシメチル)−1,4,7,10−テトラアザシクロドデカンのカドリ ニウム−錯体である請求項1に記載の 化合物。 7.一般式Iのペルフルオロアルキル含有化合物を製造する方法にあって、 a)式中のAが一般式IXである一般式Iを製造するために、一般式20: (式中、R4が水素、メチル、エチル、イソプロピル、t−ブチル又はベンジ ルである) で表わされる化合物を、一般式21: (式中、R3はR1と同じか又はその保護型であり、あるいはmが0,1、又は 2を意味し、L’がLであり、場合によっては保護型でもあり、そしてRFがペ ルフルオロ過炭素鎖である(CH2)m−L−RFである) により表わされるエポキシドと、 アルコール、エーテル、水、もしくは水と1種類の有機溶媒の混合液中、−1 0℃から180℃の温度で無機およびあるいは有機塩基を添加して反応せしめ、 そして所望により存在する保護基を開裂し、得られた錯体形成体を室温以上の温 度で、原子番号21〜29,39,42,44又は57〜83の元素の金属酸化 物又は金属塩 の少なくとも一つと反応せしめ、そしてさらに必要に応じて、存在する酸性水素 原子をカチオン、無機および/又は有機塩基、アミノ酸又はアミノ酸アミドで置 換し;あるいは、 b)式中のAが一般式VIIIである一般式Iの化合物を製造するために、一般式 20の化合物を、一般式28: (式中、R2がR1であり、Halが塩素、臭素、およびヨードであり、そして RF、L’およびR3が前記に同意である) で表わされる化合物により、公知の方法によりアルキル化し、そして所望によ り存在する保護基を開裂し、得られた錯体形成体を用いてa)と同様にして処理 し;あるいは、 c)式中のAが一般式VIIである一般式Iの化合物を製造するために、一般式 20の化合物を、一般式34: (式中、Hal’は、Hal、フッ素、−OTs又はOMsであ 残基であり、そしてL’及びRFは上記に同意である) により表わされる化合物と、公知の方法を用いて反応せしめ、そし て所望により、場合によっては存在する保護基を開裂し、得られた錯体形成体を a)と同様にして処理し;あるいは、 d)一般式Iの化合物にあって、当該式中のAが、qが数字の0である一般式 XIに同意である化合物を製造するために、一般式20の化合物を、一般式6 8: (式中、RF、L’、R2およびHalは上記に同じである) で表わされる化合物と、高温の有機溶媒中に数時間おいて反応せしめ、そして場 合によっては存在する保護基を開裂し、得られた錯体形成体をa)と同様にして 処理し;あるいは、 e)一般式Iの化合物にあって、当該式中のAが、qが数字の1である一般式 XIに同意である化合物を製造するために、一般式20の化合物を、一般式68 a: (式中、RF、L’、R3、pおよびHalは上記に同意である) により表わされる化合物と、高温の有機溶媒中に数時間おいて反応せしめ、つづ いて場合によっては存在する保護基を開裂し、得られた錯体形成体をa)と同様 にして処理する; ことを特徴とする製造方法。 8.一般式Iのペルフルオロアルキル含有化合物の製造方法にあって、 a)式中のAが一般式IIと同意である一般式Iの化合物を製造するために、一 般式IIのYがOH−基である場合には、一般式48: (式中、R4は前記に同意である) で表わされる化合物を、一般式29: (式中、R3、L’、RFは前記に同意である) により表わされるアミンと、有機溶媒中で、場合によっては無機および/又は有 機塩基を添加して、高温におき反応せしめ、そして、場合によっては存在する保 護基を開裂し、得られた錯体形成体を室温以上の温度で、原子番号21〜29, 39,42,44又は57〜83の元素の金属酸化物もしくは金属塩の少なくと も一つと反応せしめ、さらに、必要に応じて、存在する酸性水素原子をカチオン 、無機および/又は有機塩基、アミノ酸又はアミノ酸アミドと反応せしめ;ある いは、一般式IIのYが である場合には、一般式49:のジエチルエントリアミン−ペンタ酢酸のビス無水物を、同様の条件下で式29 のアミンと反応せしめ、その後は先出の例と同様に処理し;あるいは、 b)式中のAが一般式XIIと同意である一般式Iの化合物を製造するために、 ビス無水物49を、一般式67: (式中、RFとL’は前記に同意である) のピペラジン誘導体とa)と同一条件下で反応せしめ、さらに場合によっては存 在する保護基を開裂して、さらにa)と同様に処理する; ことを特徴とする製造方法。 9.一般式Iのペルフルオロアルキル含有化合物の製造方法にあって、 a)式中のAが一般式IIIと同意である一般式Iの化合物を製造するために、 一般式52: (式中、HalとR4は前記に同意である) により表わされるハロゲン炭酸誘導体を、一般式51: (式中、RF、L’、R2及びR3は前記と同意である) により表わされる化合物と、公知の方法を用いて反応せしめ、さらに場合によっ ては、得られた錯体形成体を室温以上の温度で、原子番号21〜29,39,4 2,44又は57〜83の元素の金属酸化物又は金属塩の少なくとも一つと反応 せしめ、さらに必要に応じて、存在する酸性水素原子をカチオン、無機および/ もしくは有機塩基、アミノ酸あるいはアミノ酸アミドで置換し;あるいは b)式中のAが一般式XIIIと同意である一般式Iの化合物を製造するために 、a)と同様の方法で、一般式52のハロゲン炭酸誘導体を、一般式66: (式中、RF、L’およびR2は前記に同意である) により表わされるピペラジン誘導体と反応せしめ、さらに場合によっては存在す る保護基を開裂して、さらにa)と同様にして処理する; ことを特徴とする製造方法。 10.一般式Iのペルフルオロアルキル含有化合物を製造する方法にあって、 式中のAが一般式IVである化合物を製造するために、一般式56 : (式中、R4は前記と同意である) により表わされるヒドロキシ酸又は−エステルを、一般式55: Hal−L’−RF (55) (式中、RF、L’およびHalは前記に同意である) により表わされるハロゲン化合物と、有機溶媒と緩衝液からなる混合液中、弱ア ルカリ性のpH、室温条件下に数時間かけて反応せしめ、さらに場合によっては 存在する保護基を開裂し、得られた錯体形成体を、室温以上の温度で、原子番号 21〜29,39,42,44あるいは57〜83の元素の金属酸化物又は金属 塩の少なくとも一つと反応せしめ、さらに、必要に応じて、存在する酸性水素原 子をカチオン、無機および/又は有機塩基、アミノ酸あるいはアミノ酸アミドで 置換することを特徴とする方法。 11.一般式Iのペルフルオロアルキル含有化合物の製造方法にあって、 a)式中のAが一般式Vと同意である一般式Iの化合物を製造するために、一 般式18: Hal-CH2CO2R4 (18) (式中、HalとR4は前記に同意である) により表わされるハロゲンカルボン酸エステル又は酸を、一般式39: (式中、RF、L’、及びqは前記と同意である) により表わされる化合物と、公知の方法を用いて反応せしめ、さらに場合によっ ては、得られた錯体形成体を室温以上の温度で、原子番号21〜29,39,4 2,44又は57〜83の元素の金属酸化物又は金属塩の少なくとも一つと反応 せしめ、さらに、必要に応じて、存在する酸性水素原子をカチオン、無機および /もしくは有機塩基、アミノ酸あるいはアミノ酸アミドで置換し;あるいは、 b)式中のAが一般式・と同意である一般式Iの化合物を製造するために、一 般式18のa−ハロゲンカルボン酸エステルもしくは−酸を、一般式36: (式中、L’及びRFは前記に同意である) により表わされる化合物と、公知の方法で反応せしめ、さらにa) と同様にして処理し;あるいは、 c)式中のAが一般式Xと同意である一般式Iの化合物を製造するために、一 般式18のa−ハロゲンカルボン酸エステル又は酸を、一般式70: (式中、RF、L’およびR3は前記に同意であり、そしてSgは保護基である ) により表わされる化合物と、公知の方法を用いて反応せしめ、さらにa)と同様 にして処理する; ことを特徴とする製造方法。 12.少なくとも1種類の生理的に利用可能な請求項1の化合物を含み、場合 によっては医薬品に通常使用される添加物も含む医薬品材料。 13.少なくとも1種類の生理的に利用可能な請求項1の化合物又は請求項1 2に記載の医薬品材料を1H−NMR−診断法および−スペクトロスコピ−の造 影剤として利用する方法。 14.少なくとも1種類の生理的に利用可能な請求項1の化合物又は請求項1 2の医薬品材料をレントゲン診断の造影剤として利用する方法。 15.少なくとも1種類の生理的に利用可能な請求項1の化合物又は請求項1 2の医薬品材料を放射線−診断および−治療の医薬品として利用する方法。 16.血液−プール−剤として用いる請求項13又は14の方法。 17.リンパ管造影剤として用いる請求項13又は14の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19603033A DE19603033A1 (de) | 1996-01-19 | 1996-01-19 | Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
DE19603033.1 | 1996-01-19 | ||
PCT/EP1997/000209 WO1997026017A2 (de) | 1996-01-19 | 1997-01-16 | Perfluoralkylhaltige metallkomplexe und ihre verwendung in der nmr-diagnostik |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000506511A true JP2000506511A (ja) | 2000-05-30 |
Family
ID=7783921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9525698A Ceased JP2000506511A (ja) | 1996-01-19 | 1997-01-16 | ペルフルオロアルキル含有金属錯体、その製造方法及びnmr―診断薬への応用 |
Country Status (28)
Country | Link |
---|---|
US (3) | US6468502B1 (ja) |
EP (1) | EP0874645B1 (ja) |
JP (1) | JP2000506511A (ja) |
KR (1) | KR100539041B1 (ja) |
CN (1) | CN1203898C (ja) |
AT (1) | ATE215386T1 (ja) |
AU (1) | AU716788B2 (ja) |
BG (1) | BG62914B1 (ja) |
BR (1) | BR9707053B1 (ja) |
CZ (1) | CZ298769B6 (ja) |
DE (2) | DE19603033A1 (ja) |
DK (1) | DK0874645T3 (ja) |
EE (1) | EE04298B1 (ja) |
ES (1) | ES2174215T3 (ja) |
HK (1) | HK1018404A1 (ja) |
HU (1) | HU226199B1 (ja) |
IL (1) | IL125311A (ja) |
IS (1) | IS2127B (ja) |
NO (1) | NO319680B1 (ja) |
NZ (1) | NZ330579A (ja) |
PL (1) | PL187466B1 (ja) |
PT (1) | PT874645E (ja) |
RU (1) | RU2242477C2 (ja) |
SK (1) | SK283576B6 (ja) |
TW (1) | TW542841B (ja) |
UA (1) | UA65533C2 (ja) |
WO (1) | WO1997026017A2 (ja) |
ZA (1) | ZA97419B (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19603033A1 (de) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
DE19729013A1 (de) * | 1997-07-03 | 1999-02-04 | Schering Ag | Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
DE19744004C1 (de) * | 1997-09-26 | 1999-07-22 | Schering Ag | Lipophile Metall-Komplexe für Nekrose und Infarkt-Imaging |
US6495118B1 (en) * | 1997-09-26 | 2002-12-17 | Schering Aktiengesellschaft | Lipophilic metal complexes for necrosis and infarction imaging |
DE19914101C1 (de) * | 1999-03-22 | 2000-10-12 | Schering Ag | Perfluoralkylamide, ihre Herstellung und ihre Verwendung in der Diagnostik |
US6461587B1 (en) | 1999-03-22 | 2002-10-08 | Schering Aktiengesellschaft | Perfluoroalkylamides, their production and their use in diagnosis |
DE19948651B4 (de) * | 1999-09-29 | 2006-10-05 | Schering Ag | Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung |
EP1088559A3 (de) * | 1999-09-29 | 2002-10-02 | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN | Galenische Formulierungen |
DE19948650A1 (de) * | 1999-09-29 | 2001-07-19 | Diagnostikforschung Inst | Galenische Formulierungen |
US6641797B2 (en) | 2000-08-11 | 2003-11-04 | Schering Aktiengesellschaft | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use |
DE10040381C1 (de) * | 2000-08-11 | 2002-06-06 | Schering Ag | Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung |
DE10066210B4 (de) * | 2000-08-11 | 2008-02-28 | Bayer Schering Pharma Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques |
DE10040380B4 (de) * | 2000-08-11 | 2006-03-09 | Schering Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques |
US6676928B2 (en) | 2000-08-11 | 2004-01-13 | Schering Aktiengesellschaft | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use |
US6818203B2 (en) * | 2000-08-11 | 2004-11-16 | Schering Aktiengesellschaft | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses |
DE10040858C2 (de) * | 2000-08-11 | 2003-12-18 | Schering Ag | Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung |
DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
ATE320795T1 (de) | 2001-08-03 | 2006-04-15 | Glaxo Group Ltd | Oberflächenaktive verbindungen und ihre anwendungen |
NO20015814D0 (no) | 2001-11-28 | 2001-11-28 | Amersham Health As | Metallkompleksforbindelser |
US7344704B2 (en) | 2002-07-10 | 2008-03-18 | Schering Ag | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi |
WO2004006934A2 (de) * | 2002-07-10 | 2004-01-22 | Hans Robert Kalbitzer | 1,4,7,10-tetraazacyclododecane als modulatoren des guanin-nukleotid bindenden roteins zur behandlung von tumoren |
DE10231799B4 (de) * | 2002-07-10 | 2006-10-05 | Schering Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben |
EA011516B1 (ru) | 2005-01-13 | 2009-04-28 | Синвеншен Аг | Композиционный материал и способ его изготовления |
DE102005008309A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone |
DE102005033903B4 (de) * | 2005-07-15 | 2007-08-09 | Bayer Schering Pharma Ag | Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel |
DE102005033902B3 (de) * | 2005-07-15 | 2007-04-05 | Schering Ag | Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel |
DE102006021495A1 (de) * | 2006-05-09 | 2007-11-15 | Bayer Schering Pharma Ag | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit |
EP2035044B1 (en) * | 2006-06-09 | 2013-10-16 | Koninklijke Philips N.V. | Elimination of contrast agent concentration dependency in mri |
DE102006049821A1 (de) | 2006-10-18 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung |
GB0708411D0 (en) * | 2007-05-01 | 2007-06-06 | Univ Durham | Lanthanide probes |
WO2010056590A2 (en) * | 2008-11-14 | 2010-05-20 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging |
US20170369755A1 (en) * | 2014-12-08 | 2017-12-28 | 3M Innovative Properties Company | Hydrofluoroolefins and methods for using same |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
JP7523883B2 (ja) | 2015-08-13 | 2024-07-29 | ザ ジェネラル ホスピタル コーポレイション | 分子mrイメージング用マンガン系キレートコンジュゲート |
CN110035996B (zh) | 2016-11-28 | 2022-08-09 | 拜耳医药股份公司 | 用于磁共振成像的新型高弛豫性钆螯合物 |
KR20210095168A (ko) | 2018-11-23 | 2021-07-30 | 바이엘 악티엔게젤샤프트 | 조영 매체의 제형 및 그의 제조 방법 |
US20200397924A1 (en) * | 2019-01-28 | 2020-12-24 | Hubei Tianshu Pharmaceutical Co., Ltd | Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof |
CN110922365B (zh) * | 2019-12-13 | 2021-04-27 | 山东铂源药业有限公司 | 一种高纯度轮环藤宁的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4762701A (en) | 1986-10-31 | 1988-08-09 | Smithkline Beckman Corporation | In vivo cellular tracking |
US4859584A (en) | 1986-10-31 | 1989-08-22 | Smithkline Beckman Corporation | Cell growth rate determination by measurement of changes in cyanine dye levels in plasma membranes |
US5672334A (en) | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
US5114703A (en) * | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
DE3930674A1 (de) | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
US5248498A (en) * | 1991-08-19 | 1993-09-28 | Mallinckrodt Medical, Inc. | Fullerene compositions for magnetic resonance spectroscopy and imaging |
JPH06181890A (ja) * | 1992-10-06 | 1994-07-05 | Terumo Corp | Mri造影剤 |
US5401493A (en) * | 1993-03-26 | 1995-03-28 | Molecular Biosystems, Inc. | Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same |
DE4317588C2 (de) | 1993-05-24 | 1998-04-16 | Schering Ag | Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung |
JPH0797340A (ja) * | 1993-06-03 | 1995-04-11 | Terumo Corp | Mri造影剤組成物 |
DE19603033A1 (de) * | 1996-01-19 | 1997-07-24 | Schering Ag | Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik |
US6019959A (en) * | 1997-07-31 | 2000-02-01 | Schering Aktiengesellschaft | Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis |
US6461587B1 (en) * | 1999-03-22 | 2002-10-08 | Schering Aktiengesellschaft | Perfluoroalkylamides, their production and their use in diagnosis |
EP1088559A3 (de) * | 1999-09-29 | 2002-10-02 | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN | Galenische Formulierungen |
US6641797B2 (en) * | 2000-08-11 | 2003-11-04 | Schering Aktiengesellschaft | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use |
US6676928B2 (en) * | 2000-08-11 | 2004-01-13 | Schering Aktiengesellschaft | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use |
US6818203B2 (en) * | 2000-08-11 | 2004-11-16 | Schering Aktiengesellschaft | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses |
-
1996
- 1996-01-19 DE DE19603033A patent/DE19603033A1/de not_active Withdrawn
-
1997
- 1997-01-16 AU AU15977/97A patent/AU716788B2/en not_active Ceased
- 1997-01-16 IL IL12531197A patent/IL125311A/en not_active IP Right Cessation
- 1997-01-16 CZ CZ0226398A patent/CZ298769B6/cs not_active IP Right Cessation
- 1997-01-16 CN CNB971917701A patent/CN1203898C/zh not_active Expired - Fee Related
- 1997-01-16 EE EE9800204A patent/EE04298B1/xx not_active IP Right Cessation
- 1997-01-16 WO PCT/EP1997/000209 patent/WO1997026017A2/de active IP Right Grant
- 1997-01-16 AT AT97902179T patent/ATE215386T1/de not_active IP Right Cessation
- 1997-01-16 KR KR1019980705523A patent/KR100539041B1/ko not_active IP Right Cessation
- 1997-01-16 DE DE59706863T patent/DE59706863D1/de not_active Expired - Fee Related
- 1997-01-16 HU HU9901295A patent/HU226199B1/hu not_active IP Right Cessation
- 1997-01-16 PT PT97902179T patent/PT874645E/pt unknown
- 1997-01-16 BR BRPI9707053-0A patent/BR9707053B1/pt not_active IP Right Cessation
- 1997-01-16 UA UA98084472A patent/UA65533C2/uk unknown
- 1997-01-16 PL PL97327931A patent/PL187466B1/pl not_active IP Right Cessation
- 1997-01-16 NZ NZ330579A patent/NZ330579A/xx unknown
- 1997-01-16 RU RU98115579/04A patent/RU2242477C2/ru not_active IP Right Cessation
- 1997-01-16 JP JP9525698A patent/JP2000506511A/ja not_active Ceased
- 1997-01-16 SK SK990-98A patent/SK283576B6/sk unknown
- 1997-01-16 DK DK97902179T patent/DK0874645T3/da active
- 1997-01-16 EP EP97902179A patent/EP0874645B1/de not_active Expired - Lifetime
- 1997-01-16 ES ES97902179T patent/ES2174215T3/es not_active Expired - Lifetime
- 1997-01-17 ZA ZA9700419A patent/ZA97419B/xx unknown
- 1997-01-18 TW TW086100514A patent/TW542841B/zh not_active IP Right Cessation
-
1998
- 1998-06-30 IS IS4790A patent/IS2127B/xx unknown
- 1998-07-15 BG BG102632A patent/BG62914B1/bg unknown
- 1998-07-16 NO NO19983287A patent/NO319680B1/no unknown
-
1999
- 1999-08-13 HK HK99103506A patent/HK1018404A1/xx not_active IP Right Cessation
- 1999-11-08 US US09/435,918 patent/US6468502B1/en not_active Expired - Fee Related
-
2002
- 2002-07-18 US US10/197,421 patent/US6916461B2/en not_active Expired - Fee Related
-
2004
- 2004-10-05 US US10/957,628 patent/US7226578B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000506511A (ja) | ペルフルオロアルキル含有金属錯体、その製造方法及びnmr―診断薬への応用 | |
CN102781909B (zh) | 作为显像剂的n-烷氧基酰胺共轭物 | |
JPH11510834A (ja) | カスケードポリマー錯体、その製造方法及びこれらを含有する医薬 | |
JP2000504736A (ja) | ペルフルオロアルキル含有金属錯体を含む医薬品と、その癌治療および治療放射線学への応用 | |
JP2002507977A (ja) | ペルフルオロアルキル含有のオリゴマー化合物、その製造方法およびnmr診断法におけるその使用 | |
US7618957B2 (en) | Perfluoroalkyl-containing complexes, process for their production as well as their use | |
CN101223148A (zh) | 含全氟烷基络合物、其制备方法及其应用 | |
WO2004112840A2 (en) | Peptide conjugate for magnetic resonance imaging | |
JP2004506026A (ja) | 極性基を有するペルフルオロアルキル含有錯体、その製造方法およびその使用 | |
JP5475454B2 (ja) | 過弗素化されたpeg基を有する金属キレート類、それらの製剤方法、及びそれらの使用 | |
TWI465251B (zh) | 作為顯影劑的n-烷氧基醯胺共軛物 | |
JP4878119B2 (ja) | エナンチオマー純粋な(4S,8S)−及び(4R,8R)−4−p−ニトロベンジル−8−メチル−3,6,9−トリアザ−3N,6N,9N−トリカルボキシメチル−1,11−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用 | |
CA2243316C (en) | Metal complexes that contain perfluoroalkyl, process for their production and their use in nmr diagnosis | |
CA2177271A1 (en) | 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceuticals containing them and process for their production | |
PT1590005E (pt) | Conjugados de ácidos (4s,8s)- e (4r,8r)-4-p-benzil-8- metil-3,6,9-triaza-sp 3/sp n, sp 6/sp n, sp 9/sp ntricarboximetil- 1,11-undecanóico enantiomericamente puros com biomoléculas, método para a sua preparação e sua utilização para a produção de agen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080624 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20080630 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080804 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |